Loading insider details...
Beta
Latest Form 4 (Sep 4, 2026): Exercise/Conversion of 5,144 XENE shares, $41.9K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Xenon Pharmaceuticals Inc. (XENE) | Exercise/Conversion | 5,144 | $41.9K |
| Jun 4, 2026 | Xenon Pharmaceuticals Inc. (XENE) | Exercise/Conversion | 2,645 | n/a |
| Dec 10, 2025 | Adverum Biotechnologies, Inc. (ADVM) | Tender of Shares | 5,000 | n/a |
| Jun 20, 2025 | Adverum Biotechnologies, Inc. (ADVM) | Grant/Award | 10,450 | n/a |
| Jun 6, 2025 | Xenon Pharmaceuticals Inc. (XENE) | Grant/Award | 17,012 | n/a |
| Jun 20, 2024 | Adverum Biotechnologies, Inc. (ADVM) | Grant/Award | 10,520 | n/a |
| Jun 11, 2024 | ACELYRIN, Inc. (SLRN) | Grant/Award | 92,158 | n/a |
| Jun 5, 2024 | Xenon Pharmaceuticals Inc. (XENE) | Grant/Award | 15,542 | n/a |
| Aug 24, 2023 | Xenon Pharmaceuticals Inc. (XENE) | Sale | 25,000 | $967.5K |
| Jun 13, 2023 | Adverum Biotechnologies, Inc. (ADVM) | Grant/Award | 40,000 | n/a |